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Introduction
The enzyme 5,10-methylenetetrahydrofolate reductase
(MTHFR) catalyses the reduction of 5,10-methylene-
tetrahydrofolate to 5-methyltetrahydrofolate, which is the
carbon donor for de novo methionine synthesis and DNA
methylation. Approximately 10% of Caucasian populations
are homozygous for a common C→T substitution at
nucleotide 677 of the MTHFR gene. This mutation converts
an alanine to a valine at codon 225 and is associated with
reduced enzyme activity and increased thermolability [1].
The potential influence of MTHFR activity on DNA methyla-
tion and on the availability of uridylates and thymidylates for
DNA synthesis and repair makes MTHFR an attractive can-
didate for a cancer predisposing gene [2,3].
Deficiencies in thymidylate have been shown to increase
the rate of misincorporation of uridylate into DNA and may
in turn lead to an increased rate of DNA strand breaks and
other chromosomal damage [4]. Consequently, reduced
MTHFR activity, which leads to increased levels of cytoso-
lic 5,10-methylenetetrahydrofolate available for thymidylate
synthesis, may protect cells from DNA damage induced by
uridylate misincorporation. Consistent with this model,
several independent studies have shown that the mutant
(valine) allele of MTHFR may confer a twofold reduction in
risk of colon cancer [2,5] and a fourfold reduction in risk of
acute lymphocytic leukemia [6]. Mutant MTHFR has also
been associated with a 2.8-fold increase in risk of
endometrial cancer [7] and a 2.9-fold increase in risk of
bp = basepairs; CI = confidence interval; MTHFR = 5,10-methylenetetrahydrofolate reductase; OR = odds ratio.
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Abstract
Background:  A growing body of evidence suggests that variations in the levels of folate may
contribute to the development of cancer. A functional polymorphic variant (C→T substitution at
nucleotide 677) in the 5,10-methylenetetrahydrofolate reductase (MTHFR) gene results in the
conversion of an alanine to a valine and may modify the risk of breast and other cancers.
Method: We have investigated the possible influence of this MTHFR variant on breast cancer risk in a
case-control study of 233 healthy women and 335 women who had breast cancer that occurred under
the age of 40 years, bilateral breast cancer or a family history of breast cancer.
Results: A significant excess of the valine genotypes was observed among the cases (odds ratio 1.43,
95% confidence interval 1.02–2.00). The effect was more pronounced among the cases with a breast
cancer diagnosis under the age of 40 years, with an odds ratio of 1.66 (95% confidence interval
1.12–2.41). A nonsignificant excess of the valine genotypes was observed among the cases with a
family history of breast cancer or bilateral breast cancer.
Conclusions: The low activity C677T (valine) genotype of MTHFR may increase the risk of early onset
breast cancer.
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cervical intraepithelial neoplasia [8]. In the latter situation
the increased cancer risk associated with mutant MTHFR
might be explained by impairment of DNA methylation due
to a reduction in the availability of 5-methyltetrahydrofo-
late. This is a plausible model because DNA methylation
plays a critical role in regulation of gene expression and
maintenance of genomic stability [9,10] and aberrations in
normal methylation patterns have been associated with
the development of cancer [10,11]. More recently, Stern
et al. [12] demonstrated that individuals who are homozy-
gous for the mutant C677T MTHFR polymorphism show a
higher degree of genomic DNA hypomethylation than do
homozygotes for the wild-type MTHFR.
The role of folate in breast cancer has been investigated in
several dietary studies and most have shown folate con-
sumption to be inversely related to breast cancer risk
[13–16]. By contrast, few studies have investigated the
influence of the MTHFR C677T polymorphism on breast
cancer risk. In one study the frequency of the low MTHFR
activity valine allele was reported to occur significantly
more frequently in Jewish women diagnosed with bilateral
breast cancer or combined breast and ovarian cancer
[17]. Another study of unselected breast cancer cases
among a Scottish population did not detect any associa-
tion with the C677T polymorphism and breast cancer risk
[18], although the study involved only 62 cases and 66
controls and lacked statistical power.
Given the plausible role of variations in MTHFR activity in
breast cancer susceptibility we undertook an analysis of
the C677T polymorphism in a case-control study of 335
women with breast cancer and 233 controls.
Materials and methods
Subjects
Women with breast cancer were selected on the basis of
an age at onset of less than 40 years, or a family history of
breast cancer (defined as two or more cases of breast
cancer in a first- or second-degree female relative) irre-
spective of age at onset, or bilateral breast cancer irre-
spective of family history or age at onset. All breast cancer
cohort cases were systematically ascertained through
breast clinics in the Wessex region of southern England
as described previously [19]. Briefly, women were invited
to take part in a research study, the primary goal of which
was to ascertain and verify family histories for segregation
analysis. The breast cancer cases diagnosed before
40 years of age were consecutively ascertained without
regard to family history. The group of women with bilateral
breast cancer were ascertained in the same clinics but the
selection criterion was the presence of bilateral breast
cancer diagnosed after 40 years of age. The familial breast
cancer cases consisted of women presenting to the same
clinics with a strong family history of breast or ovarian
cancer or both. Family histories were verified as far as
possible using medical records and death certificates.
Blood was taken from all recruits who consented to mole-
cular analysis for breast cancer predisposition genes. The
age range of the women included in the breast cancer
cohort was 19–79 with a mean age of 38 years. The con-
trols represent the population from which the cases arose
and consisted of 233 Caucasian female volunteers who
were either staff at the Princess Anne Hospital,
Southampton, UK or patients attending for non-neoplastic
disease conditions. The age of the controls ranged from 18
to 84 with a mean age of 39 years. For all groups normal
genomic DNA was prepared from blood lymphocytes. Epi-
demiological data such as reproductive factors, oral contra-
ceptive use, smoking habits and obesity were not obtained
for either the cases or controls. Both control and cancer
groups were drawn from the same geographical area,
which has predominantly an Anglo-Saxon population.
MTHFR genotyping
Genomic DNA from cases and controls was assessed for
the presence of the C677T mutation by PCR amplification
using an exonic primer (5′-tgaaggagaaggtgtctgcggga-3′)
and an intronic primer (5′-aggacggtgcggtgagagtg-3′) as
described previously [1]. PCRs were performed in a reac-
tion volume of 10 µl containing 50 ng of genomic DNA,
primers (25 ng of each), 1 × reaction buffer (Genepak,
New Milton, UK), 200 nM of dATP, dTTP, dGTP, dCTP
(Promega, Annandale, Australia) and 0.2 units of Taq DNA
polymerase (Taq Express, Genepak, UK). PCR conditions
consisted of an initial denaturation at 94°C for 5 minutes
followed by 35 cycles of 94°C for 30 s, 55°C for 30 s,
72°C for 60 s followed by one cycle of 72°C for 5 min.
The PCR products were digested with HinfI in a volume of
20 µl and the fragments were separated on 2.0% agarose
gels and visualized by ethidium bromide staining. The
C→T (valine) variant creates a HinfI restriction enzyme site
and produces fragments of 178 basepairs (bp) and 23 bp.
Statistical analysis
Frequency comparisons were analysed using Fisher’s
exact test. Odds ratios (ORs) and 95% confidence inter-
vals (CIs) were calculated using the relevant 2 × 2 contin-
gency tables. All statistical calculations were two-sided
and performed using InStat version 3.01 (GraphPad Soft-
ware Inc., San Diego, CA, USA). All statistical tests were
based on two-tailed probability.
Results
Table 1 shows the distribution of the C677T polymor-
phism among the 335 women in the breast cancer cohort
and 233 controls. The distribution of the alleles among the
controls is consistent with that for previously reported
control populations [6,20]. We did not observe a depar-
ture from Hardy–Weinberg equilibrium in the breast
cancer or the control groups (P = 0.62 and P = 0.37,
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The frequency of the valine allele among the breast cancer
cohort was 0.34, which was higher than that of the con-
trols (0.30), but this was not statistically significant
(P = 0.30). The combined number of valine/valine homozy-
gotes and alanine/valine heterozygotes was significantly
higher among the breast cancer cases as a whole than
among the controls (OR 1.43, 95% CI 1.02–2.00). The
significant excess of valine genotypes was only observed
among the breast cancer cases diagnosed under the age
of 40 years (OR 1.64, 95% CI 1.12–2.41). Interestingly,
the valine heterozygotes had a significantly increased OR
(OR 1.7, 95% CI 1.2–2.6) while the homozygotes did not
(OR 1.4, 95% CI 0.7–2.7). This may be due to the effect
of the small number of valine homozygotes.
Discussion
The potential influence of MTHFR activity on DNA methy-
lation and on the availability of uridylates and thymidylates
for DNA synthesis and repair makes MTHFR an attractive
candidate cancer-predisposing gene. Reduced MTHFR
activity leads to increased levels of cytosolic 5,10-methyl-
enetetrahydrofolate, which may protect cells from DNA
damage induced by uridylate misincorporation. Indeed,
several independent studies have shown that the mutant
valine allele of MTHFR  may reduce the risk of colon
cancer [2,5,20] and acute lymphocytic leukemia [6]. Con-
versely, mutant MTHFR has also been associated with an
increase in risk of endometrial cancer [7] and cervical
intraepithelial neoplasia [8]. An increased cancer risk con-
ferred by the valine allele may be explained by impairment
of DNA methylation due to a reduction in the availability of
5-methyltetrahydrofolate.
Only two previous studies have examined the relationship
between the MTHFR C677T polymorphism and breast
cancer risk. Gershoni-Baruch et al. [17] reported that the
677T allele occurred significantly more frequently in
Jewish women diagnosed with bilateral breast cancer or
combined breast and ovarian cancer. Sharp et al. [18] did
not observe any significant difference in the genotype dis-
tributions within a case-control study of unselected breast
cancers from a Scottish population. Comparison of the
number of cases that were compound homozygotes of the
low-activity 677TT genotype and/or another low-activity
MTHFR variant (1298CC) revealed a significant reduction
in risk (OR 0.26), suggesting that low MTHFR activity may
protect against breast cancer. While this association is
intriguing, the reliability of the conclusion is tempered by the
fact that the study included only 62 cases and 66 controls.
Given the plausible role of variations in MTHFR activity in
breast cancer susceptibility and the conflicting conclu-
sions of previous studies we undertook an analysis of the
C677T polymorphism in a more substantial number of
cancers and controls. Our study revealed a significant
excess of valine genotypes among the early onset breast
cancers (OR 1.43). In contrast to the study by Gershoni-
Baruch  et al. [17], we did not observe a significant
increase in the valine allele frequency among the women
diagnosed with bilateral breast cancer or with a family
history of breast cancer (although it was higher than in the
controls). The data presented by Sharp et al. [18] suggest
that low MTHFR activity is associated with a decrease
rather than an increase in breast cancer risk. The reliability
of their conclusions, however, is limited by the lack of
Available online http://breast-cancer-research.com/content/4/6/R13
Table 1
MTHFR C677T genotype distribution among breast cancers and controls
Alanine/Valine or 
Alanine/Alanine Alanine/Valine Valine/Valine Valine/Valine
P valuea P valuea P valuea P valuea Valine
Number No. (OR, No. (OR, No. (OR, No. (OR,  allele
Group of cases (%) 95% CI) (%) 95% CI) (%) 95% CI) (%) 95% CI) frequency
Controls 233 118 92  23  0.30
(50.6) (39.5) (9.9)
All breast cancer 335 140  1.00 162  0.03 33  0.55  195  0.04 0.34
(41.8) (48.4) (1.5, 1.0–2.1) (9.8) (1.2,  (58.2) (1.43, 
0.7–2.2) 1.02–2.00)
Under 40 breast cancer 203 78  1.00 104  0.01  21  0.39  125  0.01  0.36
(38.4) (51.2) (1.7, (10.4) (1.4, (61.6) (1.64, 
1.2–2.6) 0.7–2.7) 1.12–2.41)
Familial and/or bilateral 
breast  cancer 132 62 1.00 58 0.49 12 1.00 70 0.51  0.31
(47.0) (43.9) (1.2, (9.1) (1.0,  (53.0) (1.16, 
0.8–1.9) 0.5–2.1) 0.75–1.76)
aFisher’s exact test (two-sided) for the relevant genotype using the Alanine/Alanine homozygotes as reference. The odds ratio (OR) and 95%
confidence intervals (CI) are shown in parentheses.statistical power. The data from our study of 335 cases
suggests that, in fact, low MTHFR activity increases the
risk of breast cancer. We recognise that the conflicting
conclusions may be attributable to the different character-
istics of the breast cancer populations studied. Our study
included both familial and early onset breast cancers while
those of Sharp et al. [18] were unselected cases and
those of Gershoni-Baruch et al. [17] were unselected and
familial cases occurring among women of Jewish ancestry.
In conclusion, we suggest that low MTHFR activity is
associated with an increased risk of early onset breast
cancer. It is possible, however, that chance or confound-
ing factors such as ethnicity and the influence of known
risk factors such as oral contraceptive use may have gen-
erated a false positive result. Consequently it will be
important to replicate our findings in larger population-
based case-control studies. In addition, it will be important
for future studies to incorporate detailed dietary informa-
tion, because deficiencies in MTHFR activity may be com-
pensated for by increased folate intake and therefore may
confound interpretation of the genetic data.
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